The Obesity Drug That Rivals Surgery In the TRIUMPH-4 trial, retatrutide helped people with obesity lose an average of: 23.7% of their body weight when counting all participants, including those who discontinued treatment 28.7% weight loss among people who stayed on the highest dose throughout the 68-week study Dr Caroline Apovian from Brigham and Womens Hospital called the results incredible, noting that this is the first drug to show weight loss comparable to weight-loss surgery
This recalibration of appetite neurobiology supports weight loss without the fatigue or muscle loss common with extreme calorie restriction
Diarrhea, vomiting, and constipation also occurred at higher rates in treatment groups
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
J Clin Endocrinol Metab 106(2):388396
Products marketed as personalized blends with added vitamins or other ingredients, without a clear clinical rationale, are often designed to tout those additions to sidestep regulations rather than to benefit the patient
.png.jpg)
